August 2016

Contents

Editorial

• July/August 2016: Volume 17 Number 7/8

Conference reports

• 21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

• AIDS 2016: online access to conference programme

• ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

• ZERO HIV transmissions in PARTNER study: most widely reported i-Base article

• PrEP studies at AIDS 2016: includes first preclinical data with EFdA

• Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

• Once-daily raltegravir at last available: 48 week results from ONCEMRK study

• Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

• Dolutegravir is superior to boosted atazanavir in women in the ARIA study

• PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

• Sub-Saharan African countries moving quickly to recommend “Treat All”

• Efavirenz associated with suicide risk in analysis from START study

• CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

• Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

• Publications launched at AIDS 2016

• 8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.

• No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

• TB 2016, 16-17 July 2016, Durban, South Africa

• Universal treatment of multi-drug resistant TB is possible within current budgets with generic production

• Shortened nine-month MDR-TB treatment works well in children and adolescents

• Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

• 2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa

• 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA

• Modelling data might support use of low dose 400 mg efavirenz in pregnancy

• Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

Guidelines

• BHIVA antiretroviral guidelines updated (2016)

HIV prevention and transmission

• PROUD study closes leaving participants without access to PrEP

• EMA overcomes its own prejudice to approve PrEP in Europe: four years too late

• NAT legal challenge forces NHS England to reopen process for PrEP: 45-day public consultation now online

• Two large PrEP studies using two-month infusion of antibodies to prevent HIV infection: oral PrEP included for all participants

PDFs

• July/August 2016: Volume 17 Number 7/8